NCT07430059Not yet recruitingPhase 1
Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant
A Randomized, Parallel-Group Study to Assess the Safety, Tolerability, and Pharmacokinetics of Semaglutide Implant
Source: ClinicalTrials.gov · Last updated 30 Jun 2026
Brief summary (registry, in English)
The study will evaluate the safety, tolerability and drug levels of a semaglutide implant placed just under the skin for a period of 4 weeks compared to 4 weekly injections of semaglutide (Wegovy) in overweight/obese participants who are otherwise healthy..
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 10 Feb 2026
- Start date
- Jul 2026
- Primary completion date
- Dec 2026
- Lead sponsor
- Vivani Medical, Inc
- Diseases
- Obesity
- NCT number
- NCT07430059
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 20
- From Jul 2026 to the primary completion date, Dec 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- A clinically significant medical condition that could potentially affect study participation and/or personal well-being, as judged by the Investigator
Lab values
- Treatment with glucose lowering agent(s) within 3 months before Screening
Other
- Type 1 or Type 2 Diabetesa
Who the study is looking for
- BMI between 27 and 40 kg/m2 (inclusive)
- HbA1c \</= 6.0% and FPG \</+ 6.7 mmil/L
- eGFR \>/= 60 mL/m2
- No significant health issues in the opinion of the Investigator that would preclude study participation, as determined by medical history and physical examination
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.